Loss of memory B cells during chronic HIV infection is driven by Foxo3a- and TRAIL-mediated apoptosis

Julien van Grevenynghe(Université de Montréal), Rafael Cubas, Alessandra Noto(Université de Montréal), Sandrina DaFonseca(Université de Montréal), Zhong He, Yoav Peretz(Université de Montréal), Abdelali Filali‐Mouhim(Université de Montréal), Franck P. Dupuy(Université de Montréal), Francesco A. Procopio(Université de Montréal), Nicolas Chomont(Université de Montréal), Robert Balderas(BD Biosciences (United States)), Elias A. Said(Sultan Qaboos University), Mohamed‐Rachid Boulassel(McGill University), Cécile Tremblay, Jean‐Pierre Routy(McGill University), Rafick‐Pierre Sékaly(McGill University), Elias K. Haddad(McGill University)
Journal of Clinical Investigation
September 19, 2011
Cited by 99

Abstract

Loss of memory B cells occurs from the onset of HIV-1 infection and persists into the chronic stages of infection. Lack of survival of these cells, even in subjects being treated, could primarily be the consequence of an altered local microenvironment induced by HIV infection. In this study we showed that memory B cell survival was significantly decreased in aviremic successfully treated (ST) subjects compared with subjects who control viral load as a result of natural immunity (elite controller [EC]) or with uninfected control (HIV-) subjects. The lower survival levels observed in memory B cells from ST subjects were the result of disrupted IL-2 signaling that led to increased transcriptional activity of Foxo3a and increased expression of its proapoptotic target TRAIL. Notably, memory B cell survival in ST subjects was significantly enhanced by the addition of exogenous IL-2 in a Foxo3a-dependent manner. We further showed that Foxo3a silencing by siRNA resulted in decreased expression of TRAIL and apoptosis levels in memory B cells from ST subjects. Our results thus establish a direct role for Foxo3a/TRAIL signaling in the persistence of memory B cells and provide a mechanism for the reduced survival of memory B cells during HIV infection. This knowledge could be exploited for the development of therapeutic and preventative HIV vaccines.


Related Papers